Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

(2022) Federico Longo-Muñoz et al.   EUROPEAN JOURNAL OF CANCER

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan

(2022) Shun Yamamoto et al.   Scientific Reports

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

(2021) Jaume Capdevila et al.   JOURNAL OF CLINICAL ONCOLOGY

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

(2021) Tetsuhide Ito et al.   JOURNAL OF GASTROENTEROLOGY

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) M. Pavel et al.   ANNALS OF ONCOLOGY

Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts

(2020) Masafumi Ikeda et al.   PANCREATOLOGY

Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)

(2020) Ryo Shimoyama et al.   PANCREATOLOGY

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

(2020) Jianming Xu et al.   LANCET ONCOLOGY

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

(2019) James C Yao et al.   OncoTargets and Therapy

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real‐World Data from the Spanish Tumor Registry (R‐GETNE)

(2018) Barbara Nuñez‐Valdovinos et al.   ONCOLOGIST

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study

(2018) Jaume Capdevila et al.   ONCOLOGIST

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

(2018) Hitoshi Shibuya et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

(2018) Pamela L. Kunz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

(2017) Tetsuhide Ito et al.   INVESTIGATIONAL NEW DRUGS

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

(2017) Simron Singh et al.   NEUROENDOCRINOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?

(2016) Angela Lamarca et al.   CANCER TREATMENT REVIEWS

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

(2016) M. Pavel et al.   NEUROENDOCRINOLOGY

Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours

(2015) Lisa-Marie Dilz et al.   EUROPEAN JOURNAL OF CANCER

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan

(2014) Taku Aoki et al.   JOURNAL OF GASTROENTEROLOGY

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY